Overview

Study in Adolescents With Schizophrenia or Bipolar Disorder

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Open-label safety study of oral olanzapine treatment in adolescents, aged 13 to 17 years, with bipolar I disorder (manic or mixed episodes) or schizophrenia.
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Olanzapine